Fig. 5

EHD1 contributes to tumor growth and angiogenesis in vivo. a-e A549 luciferase cells stably expressing control ShRNA or EHD1 ShRNA were injected into the alar skin of nude mice, and images of the resulting tumors in the mice on days 7 and 28 are shown (a). A photograph of the tumors at day 28 post injection is shown (left), and the tumor growth curves of the mice on days 7 to 28 are presented (right) (b). The tumor weights were measured, and the data are presented as the means±SDs (n = 5, each) (c). Representative images of IHC staining for VEGFA and CD31 in xenograft tumor tissues are presented (d). Representative immunofluorescent staining of CD31 is shown (e). f-i A549-luciferase cells stably expressing EHD1 ShRNA or EHD1 ShRNA/R were injected into the alar skin of nude mice. Images of the resulting tumors in the mice on days 7 and 28 are shown (f). A photograph of the tumors at day 28 postinjection is shown (left), and the tumor growth curves of the mice on days 7 to 28 are presented (right) (g). The tumor weights were measured, and the data are presented as the means±SDs (n = 5, each) (h). Representative images of IHC staining for VEGFA and CD31 in xenograft tumor tissues are presented (i). Representative immunofluorescent staining of CD31 is shown (j). *p < 0.05